Cargando...
Risk-Benefit Profiles of Women Using Tamoxifen for Chemoprevention
BACKGROUND: Tamoxifen has been US Food and Drug Administration–approved for primary prevention of breast cancer since 1998 but has not been widely adopted, in part because of increased risk of serious side effects. Little is known about the risk-benefit profiles of women who use chemoprevention outs...
Gardado en:
| Publicado en: | J Natl Cancer Inst |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Oxford University Press
2014
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4296193/ https://ncbi.nlm.nih.gov/pubmed/25475563 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/dju354 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|